| Literature DB >> 34934932 |
Akihito Ishikita1,2, Shouji Matsushima1,2, Soichiro Ikeda1, Kosuke Okabe1, Ryohei Nishimura1,2, Tomonori Tadokoro1, Nobuyuki Enzan1,2, Taishi Yamamoto1,2, Masashi Sada1,2, Yoshitomo Tsutsui1,2, Ryo Miyake1,2, Masataka Ikeda1, Tomomi Ide3, Shintaro Kinugawa1,2, Hiroyuki Tsutsui1,2.
Abstract
Molecular mechanisms mediating cardiac hypertrophy by glucose metabolism are incompletely understood. Hexosamine biosynthesis pathway (HBP), an accessory pathway of glycolysis, is known to be involved in the attachment of O-linked N-acetylglucosamine motif (O-GlcNAcylation) to proteins, a post-translational modification. We here demonstrate that glutamine-fructose-6-phosphate amidotransferase 2 (GFAT2), a critical HBP enzyme, is a major isoform of GFAT in the heart and is increased in response to several hypertrophic stimuli, including isoproterenol (ISO). Knockdown of GFAT2 suppresses ISO-induced cardiomyocyte hypertrophy, accompanied by suppression of Akt O-GlcNAcylation and activation. Knockdown of GFAT2 does not affect anti-hypertrophic effect by Akt inhibition. Administration of glucosamine, a substrate of HBP, induces protein O-GlcNAcylation, Akt activation, and cardiomyocyte hypertrophy. In mice, 6-diazo-5-oxo-L-norleucine, an inhibitor of GFAT, attenuates ISO-induced protein O-GlcNAcylation, Akt activation, and cardiac hypertrophy. Our results demonstrate that GFAT2 mediates cardiomyocyte hypertrophy by HBP-O-GlcNAcylation-Akt pathway and could be a critical therapeutic target of cardiac hypertrophy.Entities:
Keywords: Cell biology; Classification Description: Cellular physiology; Molecular physiology
Year: 2021 PMID: 34934932 PMCID: PMC8661546 DOI: 10.1016/j.isci.2021.103517
Source DB: PubMed Journal: iScience ISSN: 2589-0042